Test drug VX-147 for APOL1-related protein in urine kidney disease
Part of Kidney & urinary clinical trials.
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have the APOL1 gene pattern G1/G1, G2/G2, or G1/G2
- You have kidney disease where urine protein is present (proteinuria)
- If you join Part B, you finished Part A and did not permanently stop the study drug
- You have not had a solid organ or bone marrow transplant
- Your blood pressure is controlled (not uncontrolled hypertension)
- You do not have diabetes and your kidney disease is not from another known cause (like sickle cell disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
This study checks if a new genetic test for the APOL1 gene works correctly. It uses samples from people who have already joined another drug trial.
This study tests an investigational drug (RVX000222) to see if it helps people with kidney failure who are on dialysis. The drug is given in two parts and may help improve heart health, which is often a concern for dialysis patients.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Hear when a new Proteinuric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.